Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza.
1. A method for improving a protective effect or enhancing the efficacy of seasonal or pandemic influenza vaccine comprising administering to a subject an effective amount of a synthetic or recombinant multimeric polypeptide comprising multiple copies of a plurality of influenza virus peptide epitopes, wherein the multimeric polypeptide has three repetitions of nine conserved linear epitopes arranged in the following block copolymer structure [E1E1E1-E2E2E2-E3E3E3-E4E4E4-E5E5E5-E6E6E6-E7E7E7-E8E8E8-E9E9E9], wherein E1 is HA 354-372 (SEQ ID NO: 82), E2 is HA 91-108 (SEQ ID NO: 48), E3 is M1 2-12 (SEQ ID NO: 25), E4 is HA 150-159 (SEQ ID NO: 52), E5 is HA 143-149 (SEQ ID NO: 51), E6 is NP 206-229 (SEQ ID NO: 64), E7 is HA 307-319 (SEQ ID NO: 59 or 89), E8 is NP 335-350 (SEQ ID NO: 69), and E9 is NP 380-393 (SEQ ID NO: 70), and wherein the multimeric polypeptide is administered 1-5 weeks prior to administration of a seasonal or pandemic vaccine.
2. The method according to claim 1 , wherein the multimeric polypeptide is administered 10-25 days prior to administration of a seasonal or pandemic influenza vaccine.
3. The method according to claim 1 , wherein the amount of seasonal or pandemic influenza vaccine administered is 15-50% of a standard dose of said vaccine.
4. The method according to claim 1 , wherein improvement in a protective effect is for influenza strains included in a seasonal or pandemic vaccine.
5. The method according to claim 1 , wherein improvement in a protective effect is for influenza strains not included in a seasonal or pandemic vaccine.
6. The method according to claim 1 , wherein improvement in a protective effect is measured as sero-protection in Hemagglutination Inhibition (HAI) response.
7. The method according to claim 1 , wherein the subject is equal to or older than 55 years of age.
8. The method according to claim 1 , wherein the polypeptide further comprises a carrier sequence.
9. The method according to claim 1 , wherein the pandemic vaccine is against human, swine or avian influenza strains.